NCT06168032 COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research
| NCT ID | NCT06168032 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking Union Medical College Hospital |
| Condition | COVID-19 Recurrent |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,224 participants |
| Start Date | 2023-12-08 |
| Primary Completion | 2026-12-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,224 participants in total. It began in 2023-12-08 with a primary completion date of 2026-12-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A prospective, open-label and parallel non-randomized control trial and biomarker research study is intended to compare incidence of repeated COVID-19 infection, severe pneumonitis and mortality between lung cancer patients undergoing systemic antitumor therapies who get vaccinated with 1 booster dose(majorly against XBB) and those who refuse. Meanwhile, a biomarker research is designed to monitor serum level dynamics of specific antibodies against COVID-19,analyze its correlation with incidence of breakthrough infection and further explore optimal periods for vaccination.
Eligibility Criteria
Inclusion Criteria: 1. Patients who agree to participate in the trial and sign the informed consents. 2. Male or female, ≥18 years old. 3. Diagnosed of lung carcinoma by histological and cytological examinations. 4. Undergoing systemic anti-tumor treatments including chemotherapy, immunotherapy, chemoimmunotherapy and targeted therapy. 5. Recorded history of COVID19 infection. 6. Sufficiently functional organs. 7. Eastern Cooperative Oncology Group performance score (PS) ranging from 0 to 2. Exclusion Criteria: 1. Life expectance less than 3 months. 2. Less than 3 months since last confirmed COVID-19 infection. 3. Patients unable to return the hospital for follow-up. 4. Patients allergic to COVID-19 vaccine. 5. Patients with histories of severe treatment-related adverse events graded 3rd or higher, including those caused by antitumor therapies or immunization except recoverable granulocytopenia.
Contact & Investigator
Mengzhao Wang, MD
PRINCIPAL INVESTIGATOR
Peking Union Medical College Hospital
Frequently Asked Questions
Who can join the NCT06168032 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying COVID-19 Recurrent. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06168032 currently recruiting?
Yes, NCT06168032 is actively recruiting participants. Contact the research team at mengzhaowang@sina.com for enrollment information.
Where is the NCT06168032 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06168032 clinical trial?
NCT06168032 is sponsored by Peking Union Medical College Hospital. The principal investigator is Mengzhao Wang, MD at Peking Union Medical College Hospital. The trial plans to enroll 1,224 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.